• 1
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893917.
  • 2
    Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2008, National Cancer Institute. Bethesda, MD., based on November 2010 SEER data submission, posted to the SEER web site, 2011.
  • 3
    INVS. Projection de l'incidence et de la mortalité par cancer en France en 2011. Rapport technique. Saint-Maurice: Institut de veille sanitaire;2011. 78p. 2011.
  • 4
    Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: International Agency for Research on Cancer, 2008. 337p.
  • 5
    Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO Classification (2008): update and future directions. Blood 2010; 116: e908.
  • 6
    Sant M, Allemani C, De AR, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008; 44: 57987.
  • 7
    Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009; 45: 104266.
  • 8
    Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica 2011; 96: 7208.
  • 9
    Storm HH, Klint A, Tryggvadottir L, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 694712.
  • 10
    Karim-Kos HE, Kiemeney LA, Louwman MW, et al. Progress against cancer in the Netherlands since the late 1980s: an epidemiological evaluation. Int J Cancer 2012; 130: 29819.
  • 11
    Allemani C, Sant M, De AR, et al. Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 2006; 107: 35260.
  • 12
    Bossard N, Velten M, Remontet L, et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007; 43: 14960.
  • 13
    Perme MP, Stare J, Esteve J. On estimation in relative survival. Biometrics 2011; 68: 11320.
  • 14
    Danieli C, Remontet L, Bossard N, et al. Estimating net survival: the importance of allowing for informative censoring. Stat Med 2012; 31: 77586.
  • 15
    Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology, 3rd edn., Geneva, Switzerland: World Health Organization, 2000. 357 p.
  • 16
    Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 15: 695708.
  • 17
    Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 230716.
  • 18
    Clarke CA, Glaser SL, Dorfman RF, et al. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 2004; 13: 13843.
  • 19
    Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 78496.
  • 20
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 9941004.
  • 21
    Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 604151.
  • 22
    Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 251420.
  • 23
    Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized Trials. J Natl Cancer Inst 2011; 103: 1799806.
  • 24
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 23542.
  • 25
    Komrokji RS, Al Ali NH, Beg MS, et al. Outcome of diffuse large B-cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk 2011; 11: 25760.
  • 26
    Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894907.
  • 27
    Bauer K, Skoetz N, Monsef I, et al. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; 8: CD007941.
  • 28
    Herbst C, Rehan FA, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; 2: CD007110.
  • 29
    Connors JM. Hodgkin's lymphoma-the great teacher. N Engl J Med 2011; 365: 2645.